EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study

Kouji Masumoto iD, Mitsuru Muto iD, Takato Sasaki iD, Mitsuhiro Shikamura iD, Tomoko Tanaka, Sho Sakui, Masakazu Miyamoto, Hiroya Nakano iD, Taisuke Kondo iD, Satoshi Ieiri iD

Pediatrics International · 2026

DOI: 10.1111/ped.70301 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Pediatrics International, 2026. Verfasst von Kouji Masumoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Agents, Parenteral Nutrition, Peptides, Short Bowel Syndrome. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with short bowel syndrome (SBS)‐associated intestinal failure (SBS‐IF) are dependent on parenteral support (PS). In Japan, teduglutide is the only GLP‐2 analog medicine indicated for these patients. There are limited data for pediatric patients, especially those with a low body weight. This study evaluated the safety and efficacy of teduglutide in Japanese pediatric patients with SBS‐IF (dependence on PS to provide ≥30% of fluid or caloric intake needs) who weighed less than 10 kg.

Methods

This phase 3, open‐label study enrolled Japanese pediatric patients with SBS‐IF. Patients weighing less than 10 kg received teduglutide 0.05 mg/kg/day subcutaneously in 28‐week treatment cycles (24 weeks of teduglutide treatment and 4 weeks of follow‐up). Adverse events, changes in PS requirements, and growth parameters were assessed.

Results

Three patients completed the study, with a mean teduglutide exposure duration of 48.9 weeks. All patients experienced treatment‐emergent adverse events (TEAEs), but none were related to the study drug or led to death or treatment discontinuation. Clinically meaningful reductions in mean PS volume (13.1%) and mean PS caloric intake (46.6%) were observed at the end of treatment from baseline. One patient achieved a reduction in PS volume of ≥20% at the end of treatment from baseline. Growth parameters showed increases in weight and height/length‐for‐age z ‐scores at the end of treatment from baseline.

Conclusion

In the three patients with SBS‐IF who weighed less than 10 kg, no new safety signals were observed following teduglutide treatment. Clinically meaningful reductions in PS were noted and there was no adverse impact on growth parameters. Trial Registration ClinicalTrials.gov registration number: NCT05027308

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal AgentsParenteral NutritionPeptidesShort Bowel SyndromeChildChild, PreschoolFemaleHumansInfantMaleBody WeightJapanTreatment Outcome

Stichwörter der Autor:innen

Japanintestinal failureparenteral nutritionpediatricsshort bowel syndrome

Substanzen

Gastrointestinal AgentsPeptidesteduglutide

Autor:innen und Institutionen

  • Department of Pediatric Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Pediatric Surgery, Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
  • Takeda Pharmaceutical Company Limited, Osaka, Japan.
  • Takeda Pharmaceutical Company Limited, Tokyo, Japan.

ORCID-Profile: Kouji Masumoto, Mitsuru Muto, Takato Sasaki, Mitsuhiro Shikamura, Hiroya Nakano, Taisuke Kondo, Satoshi Ieiri

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Masumoto, K., Muto, M., Sasaki, T., Shikamura, M., Tanaka, T., Sakui, S., Miyamoto, M., Nakano, H., Kondo, T., & Ieiri, S. (2026). Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study. Pediatrics International. https://doi.org/10.1111/ped.70301

Vancouver

Masumoto K, Muto M, Sasaki T, Shikamura M, Tanaka T, Sakui S, et al. Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study. Pediatrics International. 2026. doi:10.1111/ped.70301

BibTeX
@article{Masumoto2026,
  author = {Masumoto, Kouji and Muto, Mitsuru and Sasaki, Takato and Shikamura, Mitsuhiro and Tanaka, Tomoko and Sakui, Sho and Miyamoto, Masakazu and Nakano, Hiroya and Kondo, Taisuke and Ieiri, Satoshi},
  title = {Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open‐label study},
  journal = {Pediatrics International},
  year = {2026},
  doi = {10.1111/ped.70301}
}
Kostenlos starten →